TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12838091
Drug: Guideline-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based therapy
Study: 30677455
Drug: Rezūm System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rezūm System thermal therapy
Study: 26614889
Drug: Control (rigid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (rigid cystoscopy with simulated active treatment sounds)
Study: 24385026
Drug: Subcutaneous passive
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous passive drainage
Study: 22248352
Drug: Budesonide/formoterol (200/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (200/6 µg, two inhalations bd)
Study: 16024853
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide 2 mg
Study: 16024853
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide 5 mg
Study: 16024853
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide 13 mg
Study: 12465720
Drug: Balloon treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon treatment for 13 weeks followed by balloon for 52 weeks
Study: 12465720
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment for 13 weeks followed by balloon for 52 weeks
Study: 12465720
Drug: Balloon treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon treatment for 52 weeks
Study: 10591384
Drug: 0.9 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg/kg of rt-PA
Study: 1655262
Drug: Lisinopril, Enalapril,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril, Enalapril, Captopril
Study: 23085185
Drug: Imagining a
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imagining a vulnerable individual (e.g., elderly man)
Study: 20027350
Drug: Anaferon (pediatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaferon (pediatric formulation)
Study: 11586013
Drug: Vitamin B(12)
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B(12) cream containing avocado oil
Study: 28539168
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplementation (ONS) in the form of two bottles a day of β‐hydroxy‐β‐methylbutyrate (HMB)
Study: 29684990
Drug: 6% hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydroxyethyl starch (HES) infusion
Study: 19358990
Drug: Propofol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.5 mg/kg
Study: 10718795
Drug: Metoclopramide 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.2 mg/kg
Study: 7800186
Drug: Diazepam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.1 mg/kg)
Study: 16896962
Drug: Midazolam (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.03 mg/kg)
Study: 3287999
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical nerve stimulation with intramuscular papaveretum
Study: 3287999
Drug: Intramuscular papaveretum
Normalized name: papaveretum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular papaveretum alone
Study: 29135664
Drug: Step 1
Normalized name: Nicotine Patch Step 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step 1 (acetaminophen)
Study: 22658588
Drug: C(1h) -
Normalized name: 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: C(1h) - 6 mg kg(‐1) caffeine consumed 1 hour prior to exercise
Study: 16685123
Drug: Rigorous glycaemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rigorous glycaemic control (RC) with i.v. insulin and intravenous crystalloid
Study: 10834523
Drug: Indomethacin treatment
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin treatment
Study: 8292466
Drug: Amlodipine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (mean final dose 6.8 mg/day)
Study: 29408986
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg every 2 weeks)
Study: 16390567
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 50 mg kg(‐1) bolus + 10 mg kg(‐1) h(‐1) continuous infusion (Group III, n = 20)
Study: 14618196
Drug: Iloprost infusion
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost infusion (0.5 to 2 ng/kg/min over 6 hours)
Study: 10831007
Drug: MDI (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI (1.0 mg inhaled flunisolide)
Study: 10831007
Drug: MDI-S (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI-S (1.0 mg inhaled flunisolide with a spacer device)
Study: 10831007
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration (1.0 mg of flunisolide with 240 mL of water)
Study: 10831007
Drug: Intravenous (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (1.0 mg flunisolide by IV push)
Study: 1425884
Drug: Nicardipine 20
Normalized name: nicardipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 20 mg (acute treatment)
Study: 1425884
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with Nicardipine SR
Study: 31354158
Drug: Rivaroxaban (low-dose)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban (low-dose)
Study: 29590422
Drug: Non-pharmacologic approaches
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmacologic approaches for pain management (e.g., tai chi)
Study: 20301996
Drug: Both continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both continuous and intermittent infusion of vancomycin
Study: 14691416
Drug: Decision to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision to seek care to thrombolytic therapy (EMS)
Study: 3036020
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 4 mg
Study: 8393028
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 8 mg
Study: 28937021
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg plus amoxicillin 750 mg (4 times/day for 14 days)
Study: 28937021
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg plus amoxicillin 750 mg (4 times/day for 14 days)
Study: 28937021
Drug: Bismuth-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-containing quadruple regimen (rabeprazole 20 mg, bismuth 220 mg, amoxicillin 1000 mg, clarithromycin 500 mg, 2 times/day for 14 days)
Study: 23770332
Drug: Intradermal fractional-dose
Normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal fractional-dose IPV (ID-JI-0.1)
Study: 23770332
Drug: Full-dose intramuscular
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose intramuscular needle (IM-NS-0.5)
Study: 23770332
Drug: Full-dose intramuscular
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose intramuscular jet injector (IM-JI-0.5)
Study: 23770332
Drug: Fractional-dose intramuscular
Normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional-dose intramuscular needle (IM-NS-0.1)
Study: 23770332
Drug: Intradermal jet
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal jet injector (ID-JI-0.1)
Study: 8927880
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg retarded nifedipine + 25 mg atenolol
Study: 8927880
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg retarded nifedipine + 50 mg atenolol
Study: 23826914
Drug: Polaprezinc (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polaprezinc (150 mg/day for 4 weeks)
Study: 23826914
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no polaprezinc treatment)
Study: 21739372
Drug: Emodepside/toltrazuril suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emodepside/toltrazuril suspension (at least 0.45 mg emodepside plus 9 mg toltrazuril per kg body weight)
Study: 31164288
Drug: Community-based pulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based pulmonary rehabilitation (PR) for 3 weeks plus standard medication
Study: 19785937
Drug: Standard medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication
Study: 25512417
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg of eflornithine every 6 h for 14 days
Study: 21732833
Drug: Rifapentine (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifapentine (900 mg) plus isoniazid (900 mg) weekly for 12 weeks
Study: 21732833
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg) plus isoniazid (900 mg) twice weekly for 12 weeks
Study: 21732833
Drug: Isoniazid (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid (300 mg) daily for up to 6 years (continuous isoniazid)
Study: 21732833
Drug: Isoniazid (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid (300 mg) daily for 6 months (control group)
Study: 9266231
Drug: Alfuzosin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 2.5 mg t.i.d. for 4 weeks
Study: 9382121
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg alendronate
Study: 8336198
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg alendronate
Study: 8336198
Drug: >= 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: >= 5 mg alendronate
Study: 22074059
Drug: Cabergoline (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (0.25 mg twice weekly for 4 weeks followed by 0.5 mg twice weekly for the next 12 weeks)
Study: 19649245
Drug: Rabies vaccine
Normalized name: RABIES VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabies vaccine (Rabipur; Chiron Behring GmbH)
Study: 15599319
Drug: Everolimus 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 1.5 mg/day
Study: 1930075
Drug: Caffeine ingestion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine ingestion (3.3 mg/kg body weight)
Study: 6349363
Drug: Nitrofurantoin suppressive
Normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrofurantoin suppressive therapy
Study: 26374140
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with antioxidant nutrients (vitamin C 120 mg, β-carotene 6 mg, vitamin E 30 mg, selenium 100 µg, zinc 20 mg)
Study: 23256821
Drug: Fluid ingestion
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid ingestion (FL) - 5 ml kg(‐1) before and 2 ml kg(‐1) every 15 min
Study: 3903788
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 20 mg penbutolol plus 3 mg piretanide
Study: 30922609
Drug: 7-session modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-session modified mindfulness-based cognitive therapy over 10 weeks
Study: 25211921
Drug: Phytodrug prolit
Normalized name: Prolia
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Phytodrug prolit super septo 2 capsules 2 times a day for 4 weeks
Study: 15681169
Drug: Intravenous ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbic acid (AA) administration up to four times within 12 hours based on initial AA concentration (4x500 mg AA for <34.1 micromol/l; 2x500 mg AA for < or =56.8 micromol/l; 1x500 mg AA for < or =68.2 micromol/l)
Study: 11413075
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg per day for 4 weeks
Study: 3142454
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups exposed to 4500 m altitude after treatment.
Study: 12830444
Drug: Short daily
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short daily HD
Study: 10877245
Drug: 10% (w/w)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% (w/w) glycolic acid scalp lotion
Study: 8704119
Drug: Coconut oil
Normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut oil (63% C8:0 and 36% C10:0) at 6 g/day for 3 months (Control)
Study: 6832206
Drug: Plain uncoated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain uncoated tablet (400 mg)
Study: 6832206
Drug: Sustained-release tablet
Normalized name: Oratuss 12 Sustained-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release tablet formulation 2 (400 mg)
Study: 2245667
Drug: Intravenous aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous aminophylline
Study: 23400973
Drug: Capsaicin (Myolaxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (Myolaxin ointment)
Study: 23400973
Drug: Control (plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (plain lubricant cream)
Study: 20153216
Drug: Subcutaneous LMWH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous LMWH 40 mg once per day
Study: 20153216
Drug: Subcutaneous LMWH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous LMWH 40 mg twice per day
Study: 15717259
Drug: Immunoadjuvant prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immunoadjuvant prednisolone therapy
Study: 10673992
Drug: Relaxation training
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation training with guided imagery and L-arginine
Study: 28209505
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BTX) injection
Study: 20236700
Drug: LCZ696 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 100 mg
Study: 20236700
Drug: LCZ696 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 400 mg
Study: 24446062
Drug: LCZ696 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 (all doses)
Study: 18498914
Drug: Cefteram pivoxil
Normalized name: cefteram pivoxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefteram pivoxil powder suspension (100 mg)
Study: 12645861
Drug: Flt3 ligand
Normalized name: Allogeneic natural killer (NK) cells derived from CD34+ human placental stem/progenitor cells. The cells are expanded and differentiated in the presence of cytokines including thrombopoietin, SCF, Flt3 ligand, IL-7, IL-15 and IL-2 to generate the NK cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flt3 ligand (20 microg/kg per day) administered subcutaneously daily for 14 days on a 28‐day cycle, monthly for four months
Study: 12645861
Drug: Flt3 ligand
Normalized name: Allogeneic natural killer (NK) cells derived from CD34+ human placental stem/progenitor cells. The cells are expanded and differentiated in the presence of cytokines including thrombopoietin, SCF, Flt3 ligand, IL-7, IL-15 and IL-2 to generate the NK cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flt3 ligand with the E75 peptide vaccine administered on day 7 of each flt3 ligand cycle
Study: 12645861
Drug: Flt3 ligand
Normalized name: Allogeneic natural killer (NK) cells derived from CD34+ human placental stem/progenitor cells. The cells are expanded and differentiated in the presence of cytokines including thrombopoietin, SCF, Flt3 ligand, IL-7, IL-15 and IL-2 to generate the NK cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flt3 ligand with the E75 peptide vaccine administered on day 14 of each flt3 ligand cycle
Study: 10573704
Drug: Tazocillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazocillin (4 g piperacillin and 0.5 g tazobactam)
Study: 21617138
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day n-3 PUFA
Study: 19331721
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg) once daily for 12 weeks
Study: 26535146
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 12 weeks
Study: 8892713
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE), 0.625 mg/d
Study: 14761878
Drug: HIGH-CHO (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGH-CHO (10 g/kg body mass CHO)
Study: 14761878
Drug: LOW-CHO (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW-CHO (0.7 g/kg body mass CHO)
Study: 9389286
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide aerosol spray (110 microg in each nostril once daily)
Study: 9389286
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous solution spray (100 microg in each nostril once daily)
Study: 28334510
Drug: Testosterone cream
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cream (12.5 mg)
Study: 28334510
Drug: Testosterone cream
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cream (25 mg)
Study: 28334510
Drug: Testosterone cream
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cream (50 mg)
Study: 28334510
Drug: Testosterone cream
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cream (all doses)
Study: 22151296
Drug: NVA237 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 50 μg once daily
Study: 18180343
Drug: Dihydroartemisinin-piperaquine (three-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (three-dose regimen)
Study: 3739595
Drug: Glycopyrrolate (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (dosage ratio 2:1)
Study: 6338689
Drug: Digoxin 0.25
Normalized name: digoxin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.25 mg
Study: 10967698
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg
Study: 3125788
Drug: Fleroxacin 200
Normalized name: fleroxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 200 mg oral dose
Study: 3144542
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg oral dose
Study: 3125788
Drug: Fleroxacin multiple
Normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin multiple dosing of 800 or 1,200 mg once a day over 10 days
Study: 27630014
Drug: Omega-3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFAs (1,200 mg eicosapentaenoic acid and 600 mg docosahexaenoic acid daily)
Study: 10334517
Drug: 5‐FU infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU infusion and bolus CF with standard whole pelvic RT
Study: 10334517
Drug: Oral HU
Normalized name: Hu-PHEC Liver
DrugBank: Hu-PHEC Liver (DB18347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HU with standard whole pelvic RT
Study: 23983725
Drug: Vapocoolant spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapocoolant spray before vaccination
Study: 21565328
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) with interoceptive exposure (IE) to visceral sensations
Study: 15554982
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered by registered nurses
Study: 7880661
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg i.m. injection 1-2 h before operation
Study: 7880661
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg i.m. immediately after surgery
Study: 28263765
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (50mg)
Study: 18469247
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (5 mg/kg) with low glycemic index meal
Study: 10812390
Drug: Smectite (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smectite (2 x 6 g daily) in subgroup with small bowel volume <= 837.5 ml
Study: 10812390
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in subgroup with small bowel volume <= 837.5 ml
Study: 10812390
Drug: Smectite (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smectite (2 x 6 g daily) in subgroup with small bowel volume > 837.5 ml
Study: 10812390
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in subgroup with small bowel volume > 837.5 ml
Study: 20079321
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg adalimumab
Study: 19702711
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg triamcinolone alone
Study: 19702711
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg triamcinolone plus sequential laser
Study: 16749588
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg/day (Group B)
Study: 15310446
Drug: Customary antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customary antihypertensive treatment